These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2328507)

  • 21. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Early morning dystonia: a complication of levodopa therapy in Parkinson disease. Presentation of 4 cases].
    Molina Arjona JA; Arnal García C; Calandre Hoenigsfeld L; Bermejo Pareja F
    Med Clin (Barc); 1984 Jun; 83(2):47-9. PubMed ID: 6471944
    [No Abstract]   [Full Text] [Related]  

  • 24. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
    Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forms of dystonia in patients with Parkinson's disease.
    Kidron D; Melamed E
    Neurology; 1987 Jun; 37(6):1009-11. PubMed ID: 3587617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa.
    Durso R; Evans JE; Josephs E; Szabo GK; Evans BA; Handler JS; Jennings D; Browne TR
    Ann Neurol; 1997 Sep; 42(3):300-4. PubMed ID: 9307250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.
    Kulisevsky J; Pascual-Sedano B; Barbanoj M; Gironell A; Pagonabarraga J; García-Sánchez C
    Mov Disord; 2007 Jan; 22(1):62-7. PubMed ID: 17115388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The spectrum of levodopa-induced dyskinesias.
    Fahn S
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease.
    Ho B; Prakash R; Morgan JC; Sethi KD
    Nat Clin Pract Neurol; 2007 Sep; 3(9):526-30. PubMed ID: 17805247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.
    Sage JI; Schuh L; Heikkila RE; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):36-44. PubMed ID: 3349496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.